Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

T-REaCT Evolution of T cell reactivity against somatic mutations across human colon cancer stages with single-cell genomics and synthetic T cell specificity screening

Coordinator
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€217k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101208803

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancers are characterized by the accumulation of somatic mutations in the DNA. The human immune system can detect such mutations in cancers via T cells, which forms an important factor in the activity of clinically used cancer immunotherapies. What challenges our classic view of cancer formation are the recent breakthrough discoveries showing that somatic mutations are ubiquitously found in healthy tissues - why only some of these mutations lead to clonal outgrowths and what are the factors sustaining them?

As T cells recognizing somatic mutations are abundant in cancer, it is plausible to speculate these interactions could start early in tumor evolution. Albeit of high interest, studying this phenomenon has been technically challenging as it requires the ability to obtain mutational data at single-cell resolution and interrogating T cell specificities. The T-REaCT action aims to experimentally map the co-evolution of T cells and cells carrying somatic mutations across tumor evolution.

By combining two novel sets of tools and expertise from two competitive fields of synthetic T cell reactivity screening (mentor Dr Schumacher, Netherlands Cancer Institute, the Netherlands) with single-cell genomics (co-mentor Dr Landau, Weill Cornell Medicine and New York Genome Center, the US), we will create a roadmap of immune responses in human colon samples ranging from healthy tissue to adenomas to overt cancer.

By describing the formation of T cell reactivity against somatic mutations from pre-malignant to the earliest steps of malignant seeding, our project has the potential to revolutionize early cancer detection and the eradication of (pre-)malignant lesions through personalized immunotherapies.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsCoordinator
Joan & Sanford I. Weill Medical College of Cornell UniversityNew YorkUnited StatesAssociatedpartner
New York Genome Center, IncNew YorkUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI